{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T07:27:15Z","timestamp":1784618835355,"version":"3.55.0"},"reference-count":128,"publisher":"The Endocrine Society","issue":"2","license":[{"start":{"date-parts":[[2022,10,28]],"date-time":"2022-10-28T00:00:00Z","timestamp":1666915200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,1,17]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Context<\/jats:title><jats:p>Nonalcoholic fatty liver disease (NAFLD) is associated with obesity and type 2 diabetes (T2D), causing substantial burden from hepatic and extrahepatic complications. However, endocrinologists often follow people who are at the highest risk of its more severe form with nonalcoholic steatohepatitis or NASH (i.e., T2D or obesity with cardiometabolic risk factors). Endocrinologists are in a unique position to prevent cirrhosis in this population with early diagnosis and treatment.<\/jats:p><\/jats:sec><jats:sec><jats:title>Objective<\/jats:title><jats:p>This work aims to offer endocrinologists a practical approach for the management of patients with NAFLD, including diagnosis, fibrosis risk stratification, and referral to hepatologists.<\/jats:p><\/jats:sec><jats:sec><jats:title>Patients<\/jats:title><jats:p>(1) An asymptomatic patient with obesity and cardiometabolic risk factors, found to have hepatic steatosis; (2) a patient with T2D and NASH with clinically significant liver fibrosis; and (3) a liver transplant recipient with a history of NASH cirrhosis, with significant weight regain and with recurrent NAFLD on the transplanted organ.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>NASH can be reversed with proper management of obesity and of T2D. While no agents are currently approved for the treatment of NASH, treatment should include lifestyle changes and a broader use of structured weight-loss programs, obesity pharmacotherapy, and bariatric surgery. Diabetes medications such as pioglitazone and some glucagon-like peptide 1 receptor agonists may also improve liver histology and cardiometabolic health. Sodium-glucose cotransporter-2 inhibitors and insulin may ameliorate steatosis, but their effect on steatohepatitis remains unclear. Awareness by endocrinologists about, establishing an early diagnosis of fibrosis (ie, FIB-4, liver elastography) in patients at high-risk of cirrhosis, long-term monitoring, and timely referral to the hepatologist are all critical to curve the looming epidemic of cirrhosis from NAFLD.<\/jats:p><\/jats:sec>","DOI":"10.1210\/clinem\/dgac624","type":"journal-article","created":{"date-parts":[[2022,10,28]],"date-time":"2022-10-28T12:05:15Z","timestamp":1666958715000},"page":"483-495","source":"Crossref","is-referenced-by-count":14,"title":["Approach to the Patient With Nonalcoholic Fatty Liver Disease"],"prefix":"10.1210","volume":"108","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4357-0447","authenticated-orcid":false,"given":"Renata","family":"Belfort-DeAguiar","sequence":"first","affiliation":[{"name":"Internal Medicine Department, Endocrinology Section, Yale University , New Haven, Connecticut 06520 , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Romina","family":"Lomonaco","sequence":"additional","affiliation":[{"name":"Division of Endocrinology, Diabetes and Metabolism, University of Florida , Gainesville, Florida 32610 , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8629-418X","authenticated-orcid":false,"given":"Kenneth","family":"Cusi","sequence":"additional","affiliation":[{"name":"Division of Endocrinology, Diabetes and Metabolism, University of Florida , Gainesville, Florida 32610 , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"80","published-online":{"date-parts":[[2022,10,28]]},"reference":[{"issue":"5","key":"2023011718270106600_dgac624-B1","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1016\/j.eprac.2022.03.010","article-title":"American Association of Clinical Endocrinology Clinical Practice Guideline for the diagnosis of NAFLD in primary care and endocrinology clinics. Co-sponsored by the American Association for the Study of Liver Diseases (AASLD)","volume":"28","author":"Cusi","year":"2022","journal-title":"Endocr Pract"},{"issue":"9","key":"2023011718270106600_dgac624-B2","doi-asserted-by":"crossref","first-page":"2162","DOI":"10.2337\/dci21-0020","article-title":"Preparing for the NASH epidemic: a call to action","volume":"44","author":"Kanwal","year":"2021","journal-title":"Diabetes Care"},{"issue":"1","key":"2023011718270106600_dgac624-B3","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1002\/hep.29367","article-title":"The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases","volume":"67","author":"Chalasani","year":"2018","journal-title":"Hepatology"},{"issue":"6","key":"2023011718270106600_dgac624-B4","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1053\/j.gastro.2020.01.043","article-title":"Association between fibrosis stage and outcomes of patients with nonalcoholic fatty liver disease: a systematic review and meta-analysis","volume":"158","author":"Taylor","year":"2020","journal-title":"Gastroenterology"},{"issue":"17","key":"2023011718270106600_dgac624-B5","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1056\/NEJMoa2029349","article-title":"Prospective study of outcomes in adults with nonalcoholic fatty liver disease","volume":"385","author":"Sanyal","year":"2021","journal-title":"N Engl J Med"},{"issue":"4","key":"2023011718270106600_dgac624-B6","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1016\/j.jhep.2019.06.021","article-title":"The global epidemiology of NAFLD and NASH in patients with type 2 diabetes: a systematic review and meta-analysis","volume":"71","author":"Younossi","year":"2019","journal-title":"J Hepatol"},{"issue":"5","key":"2023011718270106600_dgac624-B7","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1002\/hep.27368","article-title":"Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up","volume":"61","author":"Ekstedt","year":"2015","journal-title":"Hepatology"},{"issue":"6","key":"2023011718270106600_dgac624-B8","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1097\/MOL.0000000000000717","article-title":"Cardiovascular risk in patients with nonalcoholic fatty liver disease: looking at the liver to shield the heart","volume":"31","author":"Cusi","year":"2020","journal-title":"Curr Opin Lipidol"},{"issue":"9","key":"2023011718270106600_dgac624-B9","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1136\/gutjnl-2020-320622","article-title":"NAFLD and increased risk of cardiovascular disease: clinical associations, pathophysiological mechanisms and pharmacological implications","volume":"69","author":"Targher","year":"2020","journal-title":"Gut"},{"issue":"11","key":"2023011718270106600_dgac624-B10","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1002\/hep4.1419","article-title":"Mortality related to nonalcoholic fatty liver disease is increasing in the United States","volume":"3","author":"Paik","year":"2019","journal-title":"Hepatol Commun"},{"key":"2023011718270106600_dgac624-B11","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.2147\/COPD.S166902","article-title":"Relationship between obstructive lung disease and non-alcoholic fatty liver disease in the Korean population: Korea National Health and Nutrition Examination Survey, 2007-2010","volume":"13","author":"Moon","year":"2018","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"issue":"6","key":"2023011718270106600_dgac624-B12","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1136\/gutjnl-2017-313884","article-title":"Non-alcoholic fatty liver disease and its relationship with cardiovascular disease and other extrahepatic diseases","volume":"66","author":"Adams","year":"2017","journal-title":"Gut"},{"issue":"2","key":"2023011718270106600_dgac624-B13","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.cgh.2017.09.041","article-title":"Racial and ethnic disparities in nonalcoholic fatty liver disease prevalence, severity, and outcomes in the United States: a systematic review and meta-analysis","volume":"16","author":"Rich","year":"2018","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"2","key":"2023011718270106600_dgac624-B14","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/j.jhep.2021.02.034","article-title":"Prospective evaluation of the prevalence of non-alcoholic fatty liver disease and steatohepatitis in a large middle-aged US cohort","volume":"75","author":"Harrison","year":"2021","journal-title":"J Hepatol"},{"issue":"6","key":"2023011718270106600_dgac624-B15","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1038\/ng.3855","article-title":"Adiposity amplifies the genetic risk of fatty liver disease conferred by multiple loci","volume":"49","author":"Stender","year":"2017","journal-title":"Nat Genet"},{"issue":"3","key":"2023011718270106600_dgac624-B16","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1002\/hep.24483","article-title":"Role of ethnicity in overweight and obese patients with nonalcoholic steatohepatitis","volume":"54","author":"Lomonaco","year":"2011","journal-title":"Hepatology"},{"issue":"3","key":"2023011718270106600_dgac624-B17","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1002\/hep.31238","article-title":"Combined effect of PNPLA3, TM6SF2, and HSD17B13 variants on risk of cirrhosis and hepatocellular carcinoma in the general population","volume":"72","author":"Gellert-Kristensen","year":"2020","journal-title":"Hepatology"},{"issue":"9","key":"2023011718270106600_dgac624-B18","doi-asserted-by":"crossref","first-page":"2139","DOI":"10.1111\/liv.12840","article-title":"Clinical value of liver ultrasound for the diagnosis of nonalcoholic fatty liver disease in overweight and obese patients","volume":"35","author":"Bril","year":"2015","journal-title":"Liver Int"},{"issue":"5","key":"2023011718270106600_dgac624-B19","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1053\/j.gastro.2021.07.049","article-title":"Clinical care pathway for the risk stratification and management of patients with nonalcoholic fatty liver disease","volume":"161","author":"Kanwal","year":"2021","journal-title":"Gastroenterology"},{"issue":"2","key":"2023011718270106600_dgac624-B20","doi-asserted-by":"crossref","first-page":"399","DOI":"10.2337\/dc20-1997","article-title":"Advanced liver fibrosis is common in patients with type 2 diabetes followed in the outpatient setting: the need for systematic screening","volume":"44","author":"Lomonaco","year":"2021","journal-title":"Diabetes Care"},{"issue":"11","key":"2023011718270106600_dgac624-B21","doi-asserted-by":"crossref","first-page":"1950","DOI":"10.1002\/oby.23263","article-title":"Type 2 diabetes mellitus increases the risk of hepatic fibrosis in individuals with obesity and nonalcoholic fatty liver disease","volume":"9","author":"Barb","year":"2021","journal-title":"Obesity (Silver Spring)"},{"issue":"2","key":"2023011718270106600_dgac624-B22","doi-asserted-by":"crossref","first-page":"519","DOI":"10.2337\/dc20-1778","article-title":"High prevalence of advanced liver fibrosis assessed by transient elastography among U.S. adults with type 2 diabetes","volume":"44","author":"Ciardullo","year":"2021","journal-title":"Diabetes Care"},{"key":"2023011718270106600_dgac624-B23","article-title":"Prevalence of liver fibrosis is more common in endocrinology clinics than in primary care or family medicine setting: Implications for patient care","volume-title":"Presented at Innovations in NAFLD Care 2022","author":"Godinez Leiva","year":"19, 2022"},{"issue":"4","key":"2023011718270106600_dgac624-B24","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/S2213-8587(22)00003-1","article-title":"A global view of the interplay between non-alcoholic fatty liver disease and diabetes","volume":"10","author":"Stefan","year":"2022","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2023011718270106600_dgac624-B25","doi-asserted-by":"crossref","first-page":"154291","DOI":"10.1016\/j.metabol.2020.154291","article-title":"Changing trends of liver transplantation and mortality from non-alcoholic fatty liver disease","volume":"111S","author":"Majumdar","year":"2020","journal-title":"Metabolism"},{"issue":"4","key":"2023011718270106600_dgac624-B26","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1016\/j.cgh.2018.05.057","article-title":"Nonalcoholic steatohepatitis is the fastest growing cause of hepatocellular carcinoma in liver transplant candidates","volume":"17","author":"Younossi","year":"2019","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"2","key":"2023011718270106600_dgac624-B27","doi-asserted-by":"crossref","first-page":"283","DOI":"10.2337\/dc19-1113","article-title":"Economic and clinical burden of nonalcoholic steatohepatitis in patients with type 2 diabetes in the U.S","volume":"43","author":"Younossi","year":"2020","journal-title":"Diabetes Care"},{"issue":"10","key":"2023011718270106600_dgac624-B28","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1038\/s41575-021-00477-7","article-title":"Defining comprehensive models of care for NAFLD","volume":"18","author":"Lazarus","year":"2021","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"1","key":"2023011718270106600_dgac624-B29","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1038\/s41575-021-00523-4","article-title":"Advancing the global public health agenda for NAFLD: a consensus statement","volume":"19","author":"Lazarus","year":"2022","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"3","key":"2023011718270106600_dgac624-B30","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1111\/liv.13994","article-title":"Causality between non-alcoholic fatty liver disease and risk of cardiovascular disease and type 2 diabetes: a meta-analysis with bias analysis","volume":"39","author":"Morrison","year":"2019","journal-title":"Liver Int"},{"issue":"3","key":"2023011718270106600_dgac624-B31","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1136\/gutjnl-2019-318813","article-title":"Epidemiology of chronic liver diseases in the USA in the past three decades","volume":"69","author":"Younossi","year":"2020","journal-title":"Gut"},{"issue":"4","key":"2023011718270106600_dgac624-B32","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/j.jhepr.2019.07.002","article-title":"From NASH to diabetes and from diabetes to NASH: mechanisms and treatment options","volume":"1","author":"Gastaldelli","year":"2019","journal-title":"JHEP Rep"},{"issue":"9","key":"2023011718270106600_dgac624-B33","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1038\/s41575-021-00448-y","article-title":"The complex link between NAFLD and type 2 diabetes mellitus\u2014mechanisms and treatments","volume":"18","author":"Targher","year":"2021","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"2","key":"2023011718270106600_dgac624-B34","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1053\/j.gastro.2007.04.068","article-title":"Relationship between hepatic\/visceral fat and hepatic insulin resistance in nondiabetic and type 2 diabetic subjects","volume":"133","author":"Gastaldelli","year":"2007","journal-title":"Gastroenterology"},{"issue":"4","key":"2023011718270106600_dgac624-B35","doi-asserted-by":"crossref","first-page":"632","DOI":"10.2337\/dc15-1876","article-title":"Metabolic impact of nonalcoholic steatohepatitis in obese patients with type 2 diabetes","volume":"39","author":"Lomonaco","year":"2016","journal-title":"Diabetes Care"},{"issue":"2","key":"2023011718270106600_dgac624-B36","doi-asserted-by":"crossref","first-page":"372","DOI":"10.2337\/dc17-1902","article-title":"Nonalcoholic fatty liver disease and risk of incident type 2 diabetes: a meta-analysis","volume":"41","author":"Mantovani","year":"2018","journal-title":"Diabetes Care"},{"issue":"8","key":"2023011718270106600_dgac624-B37","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1016\/S2468-1253(20)30077-7","article-title":"Global prevalence, incidence, and outcomes of non-obese or lean non-alcoholic fatty liver disease: a systematic review and meta-analysis","volume":"5","author":"Ye","year":"2020","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"4","key":"2023011718270106600_dgac624-B38","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1111\/liv.14044","article-title":"Association between non-alcoholic fatty liver disease and risk of atrial fibrillation in adult individuals: an updated meta-analysis","volume":"39","author":"Mantovani","year":"2019","journal-title":"Liver Int"},{"issue":"11","key":"2023011718270106600_dgac624-B39","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1016\/j.dld.2018.09.004","article-title":"Association between diastolic cardiac dysfunction and nonalcoholic fatty liver disease: a systematic review and meta-analysis","volume":"50","author":"Wijarnpreecha","year":"2018","journal-title":"Dig Liver Dis"},{"key":"2023011718270106600_dgac624-B40","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2022-327672","article-title":"Non-alcoholic fatty liver disease and risk of new-onset heart failure: an updated meta-analysis of about 11 million individuals","author":"Mantovani","year":"2022","journal-title":"Gut"},{"issue":"2","key":"2023011718270106600_dgac624-B41","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1007\/s12020-019-01982-1","article-title":"Insulin-like growth factor-1 and non-alcoholic fatty liver disease: a systemic review and meta-analysis","volume":"65","author":"Yao","year":"2019","journal-title":"Endocrine"},{"issue":"10","key":"2023011718270106600_dgac624-B42","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1089\/thy.2018.0257","article-title":"Association between primary hypothyroidism and nonalcoholic fatty liver disease: a systematic review and meta-analysis","volume":"28","author":"Mantovani","year":"2018","journal-title":"Thyroid"},{"issue":"1","key":"2023011718270106600_dgac624-B43","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1136\/jim-2015-000019","article-title":"Plasma thyroid hormone concentration is associated with hepatic triglyceride content in patients with type 2 diabetes","volume":"64","author":"Bril","year":"2016","journal-title":"J Investig Med"},{"issue":"6","key":"2023011718270106600_dgac624-B44","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0251449","article-title":"Severity of non-alcoholic steatohepatitis is not linked to testosterone concentration in patients with type 2 diabetes","volume":"16","author":"Dayton","year":"2021","journal-title":"PLoS One"},{"issue":"1","key":"2023011718270106600_dgac624-B45","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1210\/clinem\/dgab658","article-title":"Nonalcoholic fatty liver disease in women and girls with polycystic ovary syndrome","volume":"107","author":"Falzarano","year":"2022","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"2023011718270106600_dgac624-B46","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.1210\/jc.2015-1966","article-title":"High prevalence of nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus and normal plasma aminotransferase levels","volume":"100","author":"Portillo-Sanchez","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"2023011718270106600_dgac624-B47","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1002\/hep.27395","article-title":"The role of liver fat and insulin resistance as determinants of plasma aminotransferase elevation in nonalcoholic fatty liver disease","volume":"61","author":"Maximos","year":"2015","journal-title":"Hepatology"},{"issue":"0","key":"2023011718270106600_dgac624-B48","doi-asserted-by":"crossref","first-page":"1626","DOI":"10.14309\/ajg.0000000000000388","article-title":"Histologic findings of advanced fibrosis and cirrhosis in patients with nonalcoholic fatty liver disease who have normal aminotransferase levels","volume":"114","author":"Gawrieh","year":"2019","journal-title":"Am J Gastroenterol"},{"issue":"1","key":"2023011718270106600_dgac624-B49","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1038\/ajg.2016.517","article-title":"ACG clinical guideline: evaluation of abnormal liver chemistries","volume":"112","author":"Kwo","year":"2017","journal-title":"Am J Gastroenterol"},{"issue":"5","key":"2023011718270106600_dgac624-B50","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1038\/ajg.2016.453","article-title":"Age as a confounding factor for the accurate non-invasive diagnosis of advanced NAFLD fibrosis","volume":"112","author":"McPherson","year":"2017","journal-title":"Am J Gastroenterol"},{"issue":"9","key":"2023011718270106600_dgac624-B51","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.1016\/j.cgh.2018.12.031","article-title":"Diagnostic accuracy of noninvasive fibrosis models to detect change in fibrosis stage","volume":"17","author":"Siddiqui","year":"2019","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"5","key":"2023011718270106600_dgac624-B52","doi-asserted-by":"crossref","first-page":"e2008","DOI":"10.1210\/clinem\/dgab933","article-title":"Obesity modifies the performance of fibrosis biomarkers in nonalcoholic fatty liver disease","volume":"107","author":"Qadri","year":"2022","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"2023011718270106600_dgac624-B53","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1002\/hep.29113","article-title":"Liver fibrosis scores predict liver disease mortality in the United States population","volume":"66","author":"Unalp-Arida","year":"2017","journal-title":"Hepatology"},{"issue":"5","key":"2023011718270106600_dgac624-B54","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1016\/j.jhep.2020.06.007","article-title":"Repeated FIB-4 measurements can help identify individuals at risk of severe liver disease","volume":"73","author":"Hagstr\u00f6m","year":"2020","journal-title":"J Hepatol"},{"issue":"6","key":"2023011718270106600_dgac624-B55","doi-asserted-by":"crossref","first-page":"916","DOI":"10.14309\/ajg.0000000000000153","article-title":"Impact of obesity and alanine aminotransferase levels on the diagnostic accuracy for advanced liver fibrosis of noninvasive tools in patients with nonalcoholic fatty liver disease","volume":"114","author":"Petta","year":"2019","journal-title":"Am J Gastroenterol"},{"issue":"5","key":"2023011718270106600_dgac624-B56","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1136\/gutjnl-2021-324243","article-title":"Diagnostic accuracy of non-invasive tests for advanced fibrosis in patients with NAFLD: an individual patient data meta-analysis","volume":"71","author":"Mozes","year":"2021","journal-title":"Gut"},{"issue":"2","key":"2023011718270106600_dgac624-B57","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1111\/liv.14669","article-title":"Prognostic accuracy of FIB-4, NAFLD fibrosis score and APRI for NAFLD-related events: a systematic review","volume":"41","author":"Lee","year":"2021","journal-title":"Liver Int"},{"issue":"5","key":"2023011718270106600_dgac624-B58","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1053\/j.gastro.2020.12.003","article-title":"The association of histologic and noninvasive tests with adverse clinical and patient-reported outcomes in patients with advanced fibrosis due to nonalcoholic steatohepatitis","volume":"160","author":"Younossi","year":"2021","journal-title":"Gastroenterology"},{"issue":"6","key":"2023011718270106600_dgac624-B59","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1053\/j.gastro.2019.01.042","article-title":"Accuracy of FibroScan controlled attenuation parameter and liver stiffness measurement in assessing steatosis and fibrosis in patients with nonalcoholic fatty liver disease","volume":"156","author":"Eddowes","year":"2019","journal-title":"Gastroenterology"},{"issue":"1","key":"2023011718270106600_dgac624-B60","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.cgh.2018.08.069","article-title":"Range of normal liver stiffness and factors associated with increased stiffness measurements in apparently healthy individuals","volume":"17","author":"Bazerbachi","year":"2019","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"3","key":"2023011718270106600_dgac624-B61","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1053\/j.gastro.2020.11.051","article-title":"AGA clinical practice update on lifestyle modification using diet and exercise to achieve weight loss in the management of nonalcoholic fatty liver disease: expert review","volume":"160","author":"Younossi","year":"2021","journal-title":"Gastroenterology"},{"issue":"1","key":"2023011718270106600_dgac624-B62","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.jhep.2013.02.012","article-title":"The Mediterranean diet improves hepatic steatosis and insulin sensitivity in individuals with non-alcoholic fatty liver disease","volume":"59","author":"Ryan","year":"2013","journal-title":"J Hepatol"},{"issue":"2","key":"2023011718270106600_dgac624-B63","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.jhep.2019.04.013","article-title":"The beneficial effects of Mediterranean diet over low-fat diet may be mediated by decreasing hepatic fat content","volume":"71","author":"Gepner","year":"2019","journal-title":"J Hepatol"},{"issue":"3","key":"2023011718270106600_dgac624-B64","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1055\/s-0041-1723751","article-title":"Effects of Mediterranean diet in patients with nonalcoholic fatty liver disease: a systematic review, meta-analysis, and meta-regression analysis of randomized controlled trials","volume":"41","author":"Kawaguchi","year":"2021","journal-title":"Semin Liver Dis"},{"issue":"6","key":"2023011718270106600_dgac624-B65","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1016\/j.jhep.2015.11.004","article-title":"EASL-EASD-EASO clinical practice guidelines for the management of non-alcoholic fatty liver disease","volume":"64","author":"European Association for the Study of the Liver (EASL); European Association for the Study of Diabetes (EASD); European Association for the Study of Obesity (EASO)","year":"2016","journal-title":"J Hepatol"},{"issue":"2","key":"2023011718270106600_dgac624-B66","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/j.clnu.2018.12.022","article-title":"ESPEN guideline on clinical nutrition in liver disease","volume":"38","author":"Plauth","year":"2019","journal-title":"Clin Nutr"},{"issue":"6","key":"2023011718270106600_dgac624-B67","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1007\/s12072-020-10094-2","article-title":"The Asian Pacific Association for the Study of the Liver clinical practice guidelines for the diagnosis and management of metabolic associated fatty liver disease","volume":"14","author":"Eslam","year":"2020","journal-title":"Hepatol Int"},{"issue":"6","key":"2023011718270106600_dgac624-B68","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1016\/j.aohep.2020.09.006","article-title":"Latin American Association for the Study of the Liver (ALEH) practice guidance for the diagnosis and treatment of non-alcoholic fatty liver disease","volume":"19","author":"Arab","year":"2020","journal-title":"Ann Hepatol"},{"issue":"4","key":"2023011718270106600_dgac624-B69","first-page":"476","article-title":"Alcohol consumption in patients with nonalcoholic fatty liver disease: yes, or no?","volume":"34","author":"Protopapas","year":"2021","journal-title":"Ann Gastroenterol"},{"issue":"3","key":"2023011718270106600_dgac624-B70","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1002\/hep.30864","article-title":"Risks of light and moderate alcohol use in fatty liver disease: follow-up of population cohorts","volume":"71","author":"Aberg","year":"2020","journal-title":"Hepatology"},{"issue":"2","key":"2023011718270106600_dgac624-B71","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1002\/hep.30368","article-title":"Vitamin E improves transplant-free survival and hepatic decompensation among patients with nonalcoholic steatohepatitis and advanced fibrosis","volume":"71","author":"Vilar-Gomez","year":"2020","journal-title":"Hepatology"},{"issue":"10","key":"2023011718270106600_dgac624-B72","doi-asserted-by":"crossref","first-page":"1446","DOI":"10.1111\/obr.12719","article-title":"The effect of exercise training on intrahepatic triglyceride and hepatic insulin sensitivity: a systematic review and meta-analysis","volume":"19","author":"Sargeant","year":"2018","journal-title":"Obes Rev"},{"issue":"4","key":"2023011718270106600_dgac624-B73","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1007\/s00421-018-3818-y","article-title":"Effects of sprint interval training on ectopic lipids and tissue-specific insulin sensitivity in men with non-alcoholic fatty liver disease","volume":"118","author":"Sargeant","year":"2018","journal-title":"Eur J Appl Physiol"},{"issue":"1","key":"2023011718270106600_dgac624-B74","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1002\/hep.23276","article-title":"Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis","volume":"51","author":"Promrat","year":"2010","journal-title":"Hepatology"},{"key":"2023011718270106600_dgac624-B75","doi-asserted-by":"crossref","first-page":"154455","DOI":"10.1016\/j.metabol.2020.154455","article-title":"The effect of the magnitude of weight loss on non-alcoholic fatty liver disease: a systematic review and meta-analysis","volume":"115","author":"Koutoukidis","year":"2021","journal-title":"Metabolism"},{"issue":"1","key":"2023011718270106600_dgac624-B76","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.jhep.2016.08.023","article-title":"Aerobic vs. resistance exercise in non-alcoholic fatty liver disease: a systematic review","volume":"66","author":"Hashida","year":"2017","journal-title":"J Hepatol"},{"issue":"5","key":"2023011718270106600_dgac624-B77","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1053\/j.gastro.2017.12.024","article-title":"Effects of weight-loss medications on cardiometabolic risk profiles: a systematic review and network meta-analysis","volume":"154","author":"Khera","year":"2018","journal-title":"Gastroenterology"},{"issue":"12","key":"2023011718270106600_dgac624-B78","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1056\/NEJMoa2028395","article-title":"A placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis","volume":"384","author":"Newsome","year":"2021","journal-title":"N Engl J Med"},{"issue":"6","key":"2023011718270106600_dgac624-B79","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1016\/j.cgh.2018.10.017","article-title":"Complete resolution of nonalcoholic fatty liver disease after bariatric surgery: a systematic review and meta-analysis","volume":"17","author":"Lee","year":"2019","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"20","key":"2023011718270106600_dgac624-B80","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1001\/jama.2021.19569","article-title":"Association of bariatric surgery with major adverse liver and cardiovascular outcomes in patients with biopsy-proven nonalcoholic steatohepatitis","volume":"326","author":"Aminian","year":"2021","journal-title":"JAMA"},{"issue":"5","key":"2023011718270106600_dgac624-B81","doi-asserted-by":"crossref","first-page":"2266","DOI":"10.1007\/s00464-019-07017-0","article-title":"Impact of sleeve gastrectomy and Roux-en-Y gastric bypass on biopsy-proven non-alcoholic fatty liver disease","volume":"34","author":"Cherla","year":"2020","journal-title":"Surg Endosc"},{"issue":"2","key":"2023011718270106600_dgac624-B82","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1111\/ajt.15650","article-title":"Long-term outcomes in patients with obesity and renal disease after sleeve gastrectomy","volume":"20","author":"Kassam","year":"2020","journal-title":"Am J Transplant"},{"issue":"2","key":"2023011718270106600_dgac624-B83","doi-asserted-by":"crossref","first-page":"321","DOI":"10.2337\/dc20-0150","article-title":"Presence of liver steatosis is associated with greater diabetes remission after gastric bypass surgery","volume":"44","author":"Vangoitsenhoven","year":"2021","journal-title":"Diabetes Care"},{"issue":"10","key":"2023011718270106600_dgac624-B84","doi-asserted-by":"crossref","first-page":"3568","DOI":"10.3390\/nu13103568","article-title":"Reduction of major adverse cardiovascular events (MACE) after bariatric surgery in patients with obesity and cardiovascular diseases: a systematic review and meta-analysis","volume":"13","author":"Sutanto","year":"2021","journal-title":"Nutrients"},{"issue":"9","key":"2023011718270106600_dgac624-B85","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1111\/apt.16335","article-title":"Systematic review with meta-analysis: bariatric surgery reduces the incidence of hepatocellular carcinoma","volume":"53","author":"Ramai","year":"2021","journal-title":"Aliment Pharmacol Ther"},{"issue":"7","key":"2023011718270106600_dgac624-B86","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1056\/NEJMoa1600869","article-title":"Bariatric surgery versus intensive medical therapy for diabetes\u20145-year outcomes","volume":"376","author":"Schauer","year":"2017","journal-title":"N Engl J Med"},{"issue":"12","key":"2023011718270106600_dgac624-B87","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1016\/j.soard.2019.09.060","article-title":"Systematic review and meta-analysis of Roux-en-Y gastric bypass against laparoscopic sleeve gastrectomy for amelioration of NAFLD using four criteria","volume":"15","author":"Baldwin","year":"2019","journal-title":"Surg Obes Relat Dis"},{"issue":"4","key":"2023011718270106600_dgac624-B88","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1016\/j.cgh.2018.05.059","article-title":"Magnetic resonance vs transient elastography analysis of patients with nonalcoholic fatty liver disease: a systematic review and pooled analysis of individual participants","volume":"17","author":"Hsu","year":"2019","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"11","key":"2023011718270106600_dgac624-B89","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1016\/S2468-1253(21)00308-3","article-title":"Non-alcoholic fatty liver disease and risk of fatal and non-fatal cardiovascular events: an updated systematic review and meta-analysis","volume":"6","author":"Mantovani","year":"2021","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"5","key":"2023011718270106600_dgac624-B90","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1007\/s12072-021-10242-2","article-title":"First-in-Asian double-blind randomized trial to assess the efficacy and safety of insulin sensitizer in nonalcoholic steatohepatitis patients","volume":"15","author":"Huang","year":"2021","journal-title":"Hepatol Int"},{"issue":"22","key":"2023011718270106600_dgac624-B91","doi-asserted-by":"crossref","first-page":"2297","DOI":"10.1056\/NEJMoa060326","article-title":"A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis","volume":"355","author":"Belfort","year":"2006","journal-title":"N Engl J Med"},{"issue":"4","key":"2023011718270106600_dgac624-B92","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1053\/j.gastro.2008.06.047","article-title":"Randomized, placebo-controlled trial of pioglitazone in nondiabetic subjects with nonalcoholic steatohepatitis","volume":"135","author":"Aithal","year":"2008","journal-title":"Gastroenterology"},{"issue":"18","key":"2023011718270106600_dgac624-B93","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1056\/NEJMoa0907929","article-title":"Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis","volume":"362","author":"Sanyal","year":"2010","journal-title":"N Engl J Med"},{"issue":"5","key":"2023011718270106600_dgac624-B94","doi-asserted-by":"crossref","first-page":"305","DOI":"10.7326\/M15-1774","article-title":"Long-term pioglitazone treatment for patients with nonalcoholic steatohepatitis and prediabetes or type 2 diabetes mellitus: a randomized trial","volume":"165","author":"Cusi","year":"2016","journal-title":"Ann Intern Med"},{"issue":"8","key":"2023011718270106600_dgac624-B95","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.2337\/dc19-0167","article-title":"Role of vitamin E for nonalcoholic steatohepatitis in patients with type 2 diabetes: a randomized controlled trial","volume":"42","author":"Bril","year":"2019","journal-title":"Diabetes Care"},{"issue":"5","key":"2023011718270106600_dgac624-B96","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1001\/jamainternmed.2016.9607","article-title":"Thiazolidinediones and advanced liver fibrosis in nonalcoholic steatohepatitis: a meta-analysis","volume":"177","author":"Musso","year":"2017","journal-title":"JAMA Intern Med"},{"issue":"12","key":"2023011718270106600_dgac624-B97","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1056\/NEJMoa1010949","article-title":"Pioglitazone for diabetes prevention in impaired glucose tolerance","volume":"364","author":"DeFronzo","year":"2011","journal-title":"N Engl J Med"},{"issue":"10","key":"2023011718270106600_dgac624-B98","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.2337\/dc16-0798","article-title":"Pioglitazone prevents diabetes in patients with insulin resistance and cerebrovascular disease","volume":"39","author":"Inzucchi","year":"2016","journal-title":"Diabetes Care"},{"issue":"11","key":"2023011718270106600_dgac624-B99","doi-asserted-by":"crossref","first-page":"2659","DOI":"10.1111\/liv.15005","article-title":"PPAR-\u03b3-induced changes in visceral fat and adiponectin levels are associated with improvement of steatohepatitis in patients with NASH","volume":"41","author":"Gastaldelli","year":"2021","journal-title":"Liver Int"},{"key":"2023011718270106600_dgac624-B100","doi-asserted-by":"crossref","first-page":"108984","DOI":"10.1016\/j.diabres.2021.108984","article-title":"Pioglitazone even at low dosage improves NAFLD in type 2 diabetes: clinical and pathophysiological insights from a subgroup of the TOSCA.IT randomised trial","volume":"178","author":"Della Pepa","year":"2021","journal-title":"Diabetes Res Clin Pract"},{"issue":"4","key":"2023011718270106600_dgac624-B101","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1007\/s13300-017-0273-4","article-title":"Pioglitazone and the risk of bladder cancer: a meta-analysis","volume":"8","author":"Filipova","year":"2017","journal-title":"Diabetes Ther"},{"issue":"1","key":"2023011718270106600_dgac624-B102","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1210\/clinem\/dgab578","article-title":"The emerging role of glucagon-like peptide-1 receptor agonists for the management of NAFLD","volume":"107","author":"Patel Chavez","year":"2021","journal-title":"J Clin Endocrinol Metab"},{"issue":"10019","key":"2023011718270106600_dgac624-B103","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/S0140-6736(15)00803-X","article-title":"Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study","volume":"387","author":"Armstrong","year":"2016","journal-title":"Lancet"},{"issue":"10300","key":"2023011718270106600_dgac624-B104","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/S0140-6736(21)01443-4","article-title":"Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial","volume":"398","author":"Ludvik","year":"2021","journal-title":"Lancet"},{"issue":"6","key":"2023011718270106600_dgac624-B105","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1056\/NEJMoa2107519","article-title":"Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes","volume":"385","author":"Fr\u00edas","year":"2021","journal-title":"N Engl J Med"},{"issue":"10295","key":"2023011718270106600_dgac624-B106","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/S0140-6736(21)01324-6","article-title":"Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial","volume":"398","author":"Rosenstock","year":"2021","journal-title":"Lancet"},{"issue":"6","key":"2023011718270106600_dgac624-B107","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/S2213-8587(22)00070-5","article-title":"Effect of tirzepatide versus insulin degludec on liver fat content and abdominal adipose tissue in people with type 2 diabetes (SURPASS-3 MRI): a substudy of the randomised, open-label, parallel-group, phase 3 SURPASS-3 trial","volume":"10","author":"Gastaldelli","year":"2022","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"6","key":"2023011718270106600_dgac624-B108","doi-asserted-by":"crossref","first-page":"2318","DOI":"10.1002\/hep.30670","article-title":"Incretin-based therapies for the management of nonalcoholic fatty liver disease in patients with type 2 diabetes","volume":"69","author":"Cusi","year":"2019","journal-title":"Hepatology"},{"issue":"11","key":"2023011718270106600_dgac624-B109","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1007\/s11892-020-01349-1","article-title":"Role of agents for the treatment of diabetes in the management of nonalcoholic fatty liver disease","volume":"20","author":"Budd","year":"2020","journal-title":"Curr Diab Rep"},{"issue":"2","key":"2023011718270106600_dgac624-B110","doi-asserted-by":"crossref","first-page":"275","DOI":"10.2337\/dci19-0064","article-title":"Time to include nonalcoholic steatohepatitis in the management of patients with type 2 diabetes","volume":"43","author":"Cusi","year":"2020","journal-title":"Diabetes Care"},{"issue":"4","key":"2023011718270106600_dgac624-B111","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1111\/dom.13584","article-title":"Effect of canagliflozin treatment on hepatic triglyceride content and glucose metabolism in patients with type 2 diabetes","volume":"21","author":"Cusi","year":"2019","journal-title":"Diabetes Obes Metab"},{"issue":"5","key":"2023011718270106600_dgac624-B112","doi-asserted-by":"crossref","first-page":"931","DOI":"10.2337\/dc18-1569","article-title":"The SGLT2 inhibitor dapagliflozin reduces liver fat but does not affect tissue insulin sensitivity: a randomized, double-blind, placebo-controlled study with 8-week treatment in type 2 diabetes patients","volume":"42","author":"Latva-Rasku","year":"2019","journal-title":"Diabetes Care"},{"issue":"2","key":"2023011718270106600_dgac624-B113","doi-asserted-by":"crossref","first-page":"298","DOI":"10.2337\/dc19-0641","article-title":"Empagliflozin effectively lowers liver fat content in well-controlled type 2 diabetes: a randomized, double-blind, phase 4, placebo-controlled trial","volume":"43","author":"Kahl","year":"2020","journal-title":"Diabetes Care"},{"issue":"Suppl 2)","key":"2023011718270106600_dgac624-B114","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1111\/dom.12751","article-title":"Different effects of basal insulin peglispro and insulin glargine on liver enzymes and liver fat content in patients with type 1 and type 2 diabetes","volume":"18","author":"Cusi","year":"2016","journal-title":"Diabetes Obes Metab"},{"issue":"3","key":"2023011718270106600_dgac624-B115","doi-asserted-by":"crossref","first-page":"E829","DOI":"10.1152\/ajpendo.00133.2006","article-title":"Effects of insulin therapy on liver fat content and hepatic insulin sensitivity in patients with type 2 diabetes","volume":"292","author":"Juurinen","year":"2007","journal-title":"Am J Physiol Endocrinol Metab"},{"issue":"11","key":"2023011718270106600_dgac624-B116","doi-asserted-by":"crossref","first-page":"e345","DOI":"10.1097\/TP.0000000000002916","article-title":"Incidence and risks for nonalcoholic fatty liver disease and steatohepatitis post-liver transplant: systematic review and meta-analysis","volume":"103","author":"Saeed","year":"2019","journal-title":"Transplantation"},{"issue":"(1)","key":"2023011718270106600_dgac624-B117","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1097\/TP.0000000000002485","article-title":"Management of recurrent and de novo NAFLD\/NASH after liver transplantation","volume":"103","author":"Germani","year":"2019","journal-title":"Transplantation"},{"issue":"10","key":"2023011718270106600_dgac624-B118","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1038\/s41574-022-00711-5","article-title":"Metabolic mechanisms for and treatment of NAFLD or NASH occurring after liver transplantation","volume":"18","author":"Lonardo","year":"2022","journal-title":"Nat Rev Endocrinol"},{"issue":"(12)","key":"2023011718270106600_dgac624-B119","doi-asserted-by":"crossref","first-page":"3413","DOI":"10.1007\/s10620-019-05716-1","article-title":"Liver transplantation for nonalcoholic steatohepatitis: pathophysiology of recurrence and clinical challenges","volume":"64","author":"Samji","year":"2019","journal-title":"Dig Dis Sci"},{"issue":"(13)","key":"2023011718270106600_dgac624-B120","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1093\/ajhp\/zxab151","article-title":"Implementing a pharmacist-led transition of care model for posttransplant hyperglycemia","volume":"78","author":"Do","year":"2021","journal-title":"Am J Health Syst Pharm"},{"issue":"(2)","key":"2023011718270106600_dgac624-B121","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1097\/TP.0b013e3181c3c2ff","article-title":"Posttransplant hyperglycemia is associated with increased risk of liver allograft rejection","volume":"89","author":"Wallia","year":"2010","journal-title":"Transplantation"},{"issue":"6","key":"2023011718270106600_dgac624-B122","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1111\/j.1600-6143.2010.03126.x","article-title":"Evolution of causes and risk factors for mortality post-liver transplant: results of the NIDDK long-term follow-up study","volume":"10","author":"Watt","year":"2010","journal-title":"Am J Transplant"},{"issue":"2","key":"2023011718270106600_dgac624-B123","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1007\/s13300-018-0374-8","article-title":"Post-liver transplantation diabetes mellitus: a review of relevance and approach to treatment","volume":"9","author":"Pel\u00e1ez-Jaramillo","year":"2018","journal-title":"Diabetes Ther"},{"issue":"9","key":"2023011718270106600_dgac624-B124","doi-asserted-by":"crossref","first-page":"2303","DOI":"10.2337\/dc20-0498","article-title":"Efficacy and safety of short- and long-acting glucagon-like peptide 1 receptor agonists on a background of basal insulin in type 2 diabetes: a meta-analysis","volume":"43","author":"Huthmacher","year":"2020","journal-title":"Diabetes Care"},{"issue":"1","key":"2023011718270106600_dgac624-B125","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1002\/lt.23566","article-title":"Long-term management of the successful adult liver transplant: 2012 practice guideline by the American Association for the Study of Liver Diseases and the American Society of Transplantation","volume":"19","author":"Lucey","year":"2013","journal-title":"Liver Transpl"},{"issue":"2","key":"2023011718270106600_dgac624-B126","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.jacl.2019.01.011","article-title":"Management of dyslipidemia in adult solid organ transplant recipients","volume":"13","author":"Warden","year":"2019","journal-title":"J Clin Lipidol"},{"issue":"113","key":"2023011718270106600_dgac624-B127","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1038\/ki.2009.188","article-title":"KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD)","author":"Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Work Group","year":"2009","journal-title":"Kidney Int Suppl"},{"issue":"2","key":"2023011718270106600_dgac624-B128","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1177\/1060028019871891","article-title":"Clinical controversy in transplantation: tacrolimus versus cyclosporine in statin drug interactions","volume":"54","author":"Migliozzi","year":"2020","journal-title":"Ann Pharmacother"}],"container-title":["The Journal of Clinical Endocrinology &amp; Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jcem\/advance-article-pdf\/doi\/10.1210\/clinem\/dgac624\/47175185\/dgac624.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/article-pdf\/108\/2\/483\/48746438\/dgac624.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/article-pdf\/108\/2\/483\/48746438\/dgac624.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,29]],"date-time":"2023-11-29T18:47:58Z","timestamp":1701283678000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jcem\/article\/108\/2\/483\/6776153"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,28]]},"references-count":128,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2022,10,28]]},"published-print":{"date-parts":[[2023,1,17]]}},"URL":"https:\/\/doi.org\/10.1210\/clinem\/dgac624","relation":{},"ISSN":["0021-972X","1945-7197"],"issn-type":[{"value":"0021-972X","type":"print"},{"value":"1945-7197","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,2,1]]},"published":{"date-parts":[[2022,10,28]]}}}